NASDAQ: MDGLMadrigal Pharmaceuticals Inc Stock
$441.16-13.06 (-2.88%)
Updated Mar 20, 2026
MDGL Price
$441.16
Fair Value Price
N/A
Market Cap
$10.12B
52 Week Low
$265.00
52 Week High
$615.00
P/E
-34.33x
P/B
16.79x
P/S
13.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$958.40M
Earnings
-$288.28M
Gross Margin
94.1%
Operating Margin
-27.75%
Profit Margin
-30.1%
Debt to Equity
1.09
Operating Cash Flow
-$190M
Beta
0.81
Next Earnings
May 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MDGL Overview
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDGL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MDGL
Ranked#227 of 470
Ranked#227 of 470
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $31.84 | A | |
| $15.36 | A | |
| $180.62 | A |
Be the first to know about important MDGL news, forecast changes, insider trades & much more!
MDGL News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDGL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MDGL is poor value based on its book value relative to its share price (16.79x), compared to the US Biotechnology industry average (4.6x)
P/B vs Industry Valuation
MDGL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MDGL due diligence checks available for Premium users.
Valuation
MDGL fair value
Fair Value of MDGL stock based on Discounted Cash Flow (DCF)
Price
$441.16
Fair Value
$175.85
Overvalued by
150.87%
MDGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-34.33x
Industry
27.63x
Market
30.56x
MDGL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
16.79x
Industry
4.6x
MDGL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDGL's financial health
Profit margin
Revenue
$321.1M
Net Income
-$58.6M
Profit Margin
-18.2%
MDGL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MDGL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$656.9M
Debt to equity
1.09
MDGL's short-term assets ($1.25B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDGL's short-term assets ($1.25B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDGL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$133.5M
Investing
$27.6M
Financing
$9.0M
MDGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDGL vs Biotech Stocks
Madrigal Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.